KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeMD (LFMD) Cash & Equivalents (2016 - 2025)

LifeMD (LFMD) has disclosed Cash & Equivalents for 14 consecutive years, with $36.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 12.66% year-over-year to $36.8 million, compared with a TTM value of $36.8 million through Dec 2025, up 12.66%, and an annual FY2025 reading of $36.8 million, up 12.66% over the prior year.
  • Cash & Equivalents was $36.8 million for Q4 2025 at LifeMD, up from $23.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $41.3 million in Q4 2021 and bottomed at $4.0 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $23.9 million, with a median of $25.1 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents skyrocketed 3646.16% in 2021, then tumbled 90.42% in 2022.
  • Year by year, Cash & Equivalents stood at $41.3 million in 2021, then crashed by 90.42% to $4.0 million in 2022, then skyrocketed by 737.26% to $33.1 million in 2023, then dropped by 1.49% to $32.7 million in 2024, then grew by 12.66% to $36.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for LFMD at $36.8 million in Q4 2025, $23.8 million in Q3 2025, and $36.2 million in Q2 2025.